These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30711197)

  • 1. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
    Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
    Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
    Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
    Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
    Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic value of HBME-1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma.
    Cho H; Kim JY; Oh YL
    Pathol Int; 2018 Nov; 68(11):605-613. PubMed ID: 30350394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenge in the Pathological Diagnosis of the Follicular- Patterned Thyroid Lesions.
    Elsers DA; Hussein MRA; Osman MH; Mohamed GA; Hosny G
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3365-3376. PubMed ID: 34711014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
    Murtezaoglu AR; Gucer H
    Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
    Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
    Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD56 expression in benign and malignant thyroid lesions.
    Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
    Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
    Abd-El Raouf SM; Ibrahim TR
    Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
    Abouhashem NS; Talaat SM
    Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the follicular patterned thyroid lesions based on the WHO 2022 criteria with an emphasis on the grey-zone lesions.
    Misra S; Dhawan S; Badwal S; Sengupta A; Khosla A; Agarwal SK; Rao S
    Ann Diagn Pathol; 2024 Aug; 71():152282. PubMed ID: 38522359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination.
    Ma H; Xu S; Yan J; Zhang C; Qin S; Wang X; Li N
    Pol J Pathol; 2014 Oct; 65(3):202-9. PubMed ID: 25372417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study.
    Abdou AG; Abdelwahed M; Said A; Taie DM; Fahmy S
    J Immunoassay Immunochem; 2018; 39(5):521-537. PubMed ID: 30188764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical markers in the diagnosis of papillary thyroid carcinomas: The promising role of combined immunostaining using HBME-1 and CD56.
    Nechifor-Boila A; Borda A; Sassolas G; Hafdi-Nejjari Z; Borson-Chazot F; Lifante JC; Sturm N; Lavérriere MH; Berger N; Decaussin-Petrucci M
    Pathol Res Pract; 2013 Sep; 209(9):585-92. PubMed ID: 23910176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.
    Wallander M; Layfield LJ; Jarboe E; Emerson L; Liu T; Thaker H; Holden J; Tripp S
    Appl Immunohistochem Mol Morphol; 2010 May; 18(3):231-5. PubMed ID: 20042852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
    Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
    World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemistry Helps to Distinguish Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features/Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma with Other Follicular Thyroid Lesions.
    Chuang HW; Wang JS; Tsai JW; Hsu CT; Lin KJ
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833464
    [No Abstract]   [Full Text] [Related]  

  • 18. HBME-1 and CD15 immunocytochemistry in the follicular variant of thyroid papillary carcinoma.
    Ohta M; Ookoshi T; Naiki H; Imamura Y
    Pathol Int; 2015 Mar; 65(3):119-25. PubMed ID: 25597783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP.
    Tastekin E; Keskin E; Can N; Canberk S; Mut A; Erdogan E; Asa N; Güldiken S; Sezer A; Azatcam M
    Pol J Pathol; 2019; 70(4):286-294. PubMed ID: 32146798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.